Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives

PEG比率 医学 药理学 抗体 免疫学 业务 财务
作者
Sherif A. Gaballa,Taro Shimizu,Hidenori Ando,Haruka Takata,Sherif E. Emam,Eslam Ramadan,Youssef Wahib Naguib,Fatma Mohammed Mady,Khaled A. Khaled,Tatsuhiro Ishida
出处
期刊:Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:113 (3): 555-578 被引量:57
标识
DOI:10.1016/j.xphs.2023.11.001
摘要

Polyethylene glycol (PEG) is a versatile polymer that is used in numerous pharmaceutical applications like the food industry, a wide range of disinfectants, cosmetics, and many commonly used household products. PEGylation is the term used to describe the covalent attachment of PEG molecules to nanocarriers, proteins and peptides, and it is used to prolong the circulation half-life of the PEGylated products. Consequently, PEGylation improves the efficacy of PEGylated therapeutics. However, after four decades of research and more than two decades of clinical applications, an unappealing side of PEGylation has emerged. PEG immunogenicity and antigenicity are remarkable challenges that confound the widespread clinical application of PEGylated therapeutics — even those under clinical trials — as anti-PEG antibodies (Abs) are commonly reported following the systemic administration of PEGylated therapeutics. Furthermore, pre-existing anti-PEG Abs have also been reported in healthy individuals who have never been treated with PEGylated therapeutics. The circulating anti-PEG Abs, both treatment-induced and pre-existing, selectively bind to PEG molecules of the administered PEGylated therapeutics inducing activation of the complement system, which results in remarkable clinical implications with varying severity. These include increased blood clearance of the administered PEGylated therapeutics through what is known as the accelerated blood clearance (ABC) phenomenon and initiation of serious adverse effects through complement activation-related pseudoallergic reactions (CARPA). Therefore, the US FDA industry guidelines have recommended the screening of anti-PEG Abs, in addition to Abs against PEGylated proteins, in the clinical trials of PEGylated protein therapeutics. In addition, strategies revoking the immunogenic response against PEGylated therapeutics without compromising their therapeutic efficacy are important for the further development of advanced PEGylated therapeutics and drug-delivery systems.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张正发布了新的文献求助10
刚刚
1秒前
贾文浩发布了新的文献求助10
1秒前
识时务这也完成签到,获得积分10
1秒前
CodeCraft的应助被小费爱学习采纳,获得10
1秒前
1秒前
勤奋一一的应助被CarryLJR采纳,获得10
1秒前
科研通AI6.4的应助被rhx采纳,获得10
2秒前
cdercder的应助被甜甜的悲采纳,获得10
3秒前
3秒前
4秒前
CipherSage的应助被米卡采纳,获得10
4秒前
5秒前
科研通AI6.4的应助被369ninja采纳,获得10
5秒前
syi完成签到 ,获得积分10
5秒前
6秒前
6秒前
完美世界的应助被丰富的德天采纳,获得10
6秒前
达分歧发布了新的文献求助10
8秒前
佚名完成签到,获得积分10
8秒前
Running完成签到 ,获得积分10
9秒前
9秒前
husm完成签到,获得积分10
10秒前
乐空思的应助被哈哈哈采纳,获得50
10秒前
11秒前
Fan完成签到,获得积分10
11秒前
鑫淼发布了新的文献求助30
12秒前
茶暖完成签到,获得积分10
12秒前
kmkz发布了新的文献求助10
12秒前
12秒前
旺仔QQ糖完成签到 ,获得积分10
13秒前
结实寒梦完成签到 ,获得积分10
13秒前
13秒前
大个的应助被蓝斯登采纳,获得10
13秒前
14秒前
subinur完成签到,获得积分10
14秒前
Hope完成签到,获得积分10
15秒前
15秒前
wh完成签到,获得积分10
15秒前
晚晚完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463